ID   PLK4_HUMAN              Reviewed;         970 AA.
AC   O00444; B2RAL0; B7Z837; B7Z8G7; Q8IYF0; Q96Q95; Q9UD84; Q9UDE2;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2007, sequence version 3.
DT   10-MAY-2017, entry version 161.
DE   RecName: Full=Serine/threonine-protein kinase PLK4;
DE            EC=2.7.11.21;
DE   AltName: Full=Polo-like kinase 4;
DE            Short=PLK-4;
DE   AltName: Full=Serine/threonine-protein kinase 18;
DE   AltName: Full=Serine/threonine-protein kinase Sak;
GN   Name=PLK4; Synonyms=SAK, STK18;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS THR-232 AND
RP   ASP-830.
RC   TISSUE=Lung;
RA   Karn T., Holtrich U., Wolf G., Hock B., Strebhardt K.,
RA   Ruebsamen-Waigmann H.;
RT   "Human SAK related to the PLK/polo family of cell cycle kinases shows
RT   high mRNA expression in testis.";
RL   Oncol. Rep. 4:505-510(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION BY TEC, AND
RP   VARIANTS THR-232 AND ASP-830.
RC   TISSUE=Blood;
RX   PubMed=11489907; DOI=10.1074/jbc.M106249200;
RA   Yamashita Y., Kajigaya S., Yoshida K., Ueno S., Ota J., Ohmine K.,
RA   Ueda M., Miyazato A., Ohya K., Kitamura T., Ozawa K., Mano H.;
RT   "Sak serine-threonine kinase acts as an effector of Tec tyrosine
RT   kinase.";
RL   J. Biol. Chem. 276:39012-39020(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   VARIANTS THR-232 AND ASP-830.
RC   TISSUE=Testis, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 134-196.
RX   PubMed=8260651; DOI=10.1006/smim.1993.1041;
RA   Mills G.B., Schmandt R., Gibson S., Leung B., Hill M., May C.,
RA   Shi Y.F., Branch D.R., Radvanyi L., Truitt K.E., Imboden J.;
RT   "Transmembrane signaling by the interleukin-2 receptor: progress and
RT   conundrums.";
RL   Semin. Immunol. 5:345-364(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 135-196.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=1311287; DOI=10.1002/ijc.2910500419;
RA   Lehtola L., Partanen J., Sistonen L., Korhonen J., Warri A.,
RA   Harkonen P., Clarke R., Alitalo K.;
RT   "Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs
RT   expressed in MCF-7 breast-cancer cells.";
RL   Int. J. Cancer 50:598-603(1992).
RN   [7]
RP   FUNCTION.
RX   PubMed=16326102; DOI=10.1016/j.cub.2005.11.042;
RA   Bettencourt-Dias M., Rodrigues-Martins A., Carpenter L.,
RA   Riparbelli M., Lehmann L., Gatt M.K., Carmo N., Balloux F.,
RA   Callaini G., Glover D.M.;
RT   "SAK/PLK4 is required for centriole duplication and flagella
RT   development.";
RL   Curr. Biol. 15:2199-2207(2005).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-154.
RX   PubMed=16244668; DOI=10.1038/ncb1320;
RA   Habedanck R., Stierhof Y.-D., Wilkinson C.J., Nigg E.A.;
RT   "The Polo kinase Plk4 functions in centriole duplication.";
RL   Nat. Cell Biol. 7:1140-1146(2005).
RN   [9]
RP   INDUCTION BY TP53.
RX   PubMed=15967108; DOI=10.1593/neo.04325;
RA   Li J., Tan M., Li L., Pamarthy D., Lawrence T.S., Sun Y.;
RT   "SAK, a new polo-like kinase, is transcriptionally repressed by p53
RT   and induces apoptosis upon RNAi silencing.";
RL   Neoplasia 7:312-323(2005).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17681131; DOI=10.1016/j.devcel.2007.07.002;
RA   Kleylein-Sohn J., Westendorf J., Le Clech M., Habedanck R.,
RA   Stierhof Y.-D., Nigg E.A.;
RT   "Plk4-induced centriole biogenesis in human cells.";
RL   Dev. Cell 13:190-202(2007).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF LYS-41 AND THR-170.
RX   PubMed=18239451; DOI=10.4161/cc.7.4.5387;
RA   Bonni S., Ganuelas M.L., Petrinac S., Hudson J.W.;
RT   "Human Plk4 phosphorylates Cdc25C.";
RL   Cell Cycle 7:545-547(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-401, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   FUNCTION, AND MUTAGENESIS OF LYS-41 AND THR-170.
RX   PubMed=19164942; DOI=10.4161/cc.8.2.7355;
RA   Petrinac S., Ganuelas M.L., Bonni S., Nantais J., Hudson J.W.;
RT   "Polo-like kinase 4 phosphorylates Chk2.";
RL   Cell Cycle 8:327-329(2009).
RN   [15]
RP   INDUCTION.
RX   PubMed=19454482; DOI=10.1242/jcs.036715;
RA   Kuriyama R., Bettencourt-Dias M., Hoffmann I., Arnold M., Sandvig L.;
RT   "Gamma-tubulin-containing abnormal centrioles are induced by
RT   insufficient Plk4 in human HCT116 colorectal cancer cells.";
RL   J. Cell Sci. 122:2014-2023(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-401 AND SER-817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   INTERACTION WITH CEP152.
RX   PubMed=21059844; DOI=10.1083/jcb.201007107;
RA   Cizmecioglu O., Arnold M., Bahtz R., Settele F., Ehret L.,
RA   Haselmann-Weiss U., Antony C., Hoffmann I.;
RT   "Cep152 acts as a scaffold for recruitment of Plk4 and CPAP to the
RT   centrosome.";
RL   J. Cell Biol. 191:731-739(2010).
RN   [18]
RP   INTERACTION WITH CEP152.
RX   PubMed=20852615; DOI=10.1038/nature09445;
RA   Dzhindzhev N.S., Yu Q.D., Weiskopf K., Tzolovsky G.,
RA   Cunha-Ferreira I., Riparbelli M., Rodrigues-Martins A.,
RA   Bettencourt-Dias M., Callaini G., Glover D.M.;
RT   "Asterless is a scaffold for the onset of centriole assembly.";
RL   Nature 467:714-718(2010).
RN   [19]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22020124; DOI=10.1038/emboj.2011.378;
RA   Tang C.J., Lin S.Y., Hsu W.B., Lin Y.N., Wu C.T., Lin Y.C.,
RA   Chang C.W., Wu K.S., Tang T.K.;
RT   "The human microcephaly protein STIL interacts with CPAP and is
RT   required for procentriole formation.";
RL   EMBO J. 30:4790-4804(2011).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF FBXW5.
RX   PubMed=21725316; DOI=10.1038/ncb2282;
RA   Puklowski A., Homsi Y., Keller D., May M., Chauhan S., Kossatz U.,
RA   Grunwald V., Kubicka S., Pich A., Manns M.P., Hoffmann I., Gonczy P.,
RA   Malek N.P.;
RT   "The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets
RT   HsSAS-6 to control centrosome duplication.";
RL   Nat. Cell Biol. 13:1004-1009(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-665, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   INVOLVEMENT IN MCPHCR.
RX   PubMed=25344692; DOI=10.1038/ng.3122;
RA   Martin C.A., Ahmad I., Klingseisen A., Hussain M.S., Bicknell L.S.,
RA   Leitch A., Nuernberg G., Toliat M.R., Murray J.E., Hunt D., Khan F.,
RA   Ali Z., Tinschert S., Ding J., Keith C., Harley M.E., Heyn P.,
RA   Mueller R., Hoffmann I., Daire V.C., Dollfus H., Dupuis L.,
RA   Bashamboo A., McElreavey K., Kariminejad A., Mendoza-Londono R.,
RA   Moore A.T., Saggar A., Schlechter C., Weleber R., Thiele H.,
RA   Altmueller J., Hoehne W., Hurles M.E., Noegel A.A., Baig S.M.,
RA   Nuernberg P., Jackson A.P.;
RT   "Mutations in PLK4, encoding a master regulator of centriole
RT   biogenesis, cause microcephaly, growth failure and retinopathy.";
RL   Nat. Genet. 46:1283-1292(2014).
RN   [23]
RP   INTERACTION WITH CEP78, AND SUBCELLULAR LOCATION.
RX   PubMed=27246242; DOI=10.1242/jcs.184093;
RA   Brunk K., Zhu M., Baerenz F., Kratz A.S., Haselmann-Weiss U.,
RA   Antony C., Hoffmann I.;
RT   "Cep78 is a new centriolar protein involved in Plk4-induced centriole
RT   overduplication.";
RL   J. Cell Sci. 129:2713-2718(2016).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 2-275.
RG   New York structural genomix research consortium (NYSGXRC);
RT   "Crystal structure of PLK4 kinase.";
RL   Submitted (JUN-2009) to the PDB data bank.
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-86; HIS-146; THR-226; THR-232;
RP   LEU-317; ASP-449; SER-519 AND ASP-830.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that plays a central
CC       role in centriole duplication. Able to trigger procentriole
CC       formation on the surface of the parental centriole cylinder,
CC       leading to the recruitment of centriole biogenesis proteins such
CC       as SASS6, CENPJ/CPAP, CCP110, CEP135 and gamma-tubulin. When
CC       overexpressed, it is able to induce centrosome amplification
CC       through the simultaneous generation of multiple procentrioles
CC       adjoining each parental centriole during S phase. Phosphorylates
CC       'Ser-151' of FBXW5 during the G1/S transition, leading to inhibit
CC       FBXW5 ability to ubiquitinate SASS6. Its central role in centriole
CC       replication suggests a possible role in tumorigenesis, centrosome
CC       aberrations being frequently observed in tumors. Also involved in
CC       deuterosome-mediated centriole amplification in multiciliated that
CC       can generate more than 100 centrioles. Also involved in
CC       trophoblast differentiation by phosphorylating HAND1, leading to
CC       disrupt the interaction between HAND1 and MDFIC and activate
CC       HAND1. Phosphorylates CDC25C and CHEK2. Required for the
CC       recruitment of STIL to the centriole and for STIL-mediated
CC       centriole amplification (PubMed:22020124).
CC       {ECO:0000269|PubMed:16244668, ECO:0000269|PubMed:16326102,
CC       ECO:0000269|PubMed:17681131, ECO:0000269|PubMed:18239451,
CC       ECO:0000269|PubMed:19164942, ECO:0000269|PubMed:21725316,
CC       ECO:0000269|PubMed:22020124}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with CEP152 (via N-
CC       terminus). Interacts with CEP78; this interaction may be important
CC       for proper PLK4 localization to the centriole and PLK4-induced
CC       overduplication of centrioles (PubMed:27246242).
CC       {ECO:0000250|UniProtKB:Q64702, ECO:0000269|PubMed:20852615,
CC       ECO:0000269|PubMed:21059844, ECO:0000269|PubMed:27246242}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-746202, EBI-746202;
CC       P36575:ARR3; NbExp=3; IntAct=EBI-746202, EBI-718116;
CC       Q9NX04:C1orf109; NbExp=3; IntAct=EBI-746202, EBI-8643161;
CC       Q14241:ELOA; NbExp=5; IntAct=EBI-746202, EBI-742350;
CC       P31947:SFN; NbExp=2; IntAct=EBI-746202, EBI-476295;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome, centriole
CC       {ECO:0000269|PubMed:22020124, ECO:0000269|PubMed:27246242}.
CC       Nucleus, nucleolus {ECO:0000250}. Cleavage furrow. Note=Component
CC       of the deuterosome, a structure that promotes de novo centriole
CC       amplification in multiciliated cells that can generate more than
CC       100 centrioles. Associates with centrioles throughout the cell
CC       cycle. According to PubMed:16244668, it is not present at cleavage
CC       furrows.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O00444-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00444-2; Sequence=VSP_038117;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=O00444-3; Sequence=VSP_038116;
CC         Note=No experimental confirmation available.;
CC   -!- INDUCTION: Down-regulated in HCT 116 colorectal cancer cells,
CC       leading to aberrant centrioles composed of disorganized
CC       cylindrical microtubules and displaced appendages. Down-regulated
CC       by p53/TP53. {ECO:0000269|PubMed:15967108,
CC       ECO:0000269|PubMed:19454482}.
CC   -!- PTM: Ubiquitinated; leading to its degradation by the proteasome.
CC       {ECO:0000250}.
CC   -!- PTM: Tyrosine-phosphorylated by TEC.
CC       {ECO:0000269|PubMed:11489907}.
CC   -!- DISEASE: Microcephaly and chorioretinopathy, autosomal recessive,
CC       2 (MCCRP2) [MIM:616171]: A severe disorder characterized by
CC       microcephaly, delayed psychomotor development, growth retardation
CC       with dwarfism, and ocular abnormalities.
CC       {ECO:0000269|PubMed:25344692}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y13115; CAA73575.1; -; mRNA.
DR   EMBL; AB006972; BAB69958.1; -; mRNA.
DR   EMBL; AK302858; BAH13823.1; -; mRNA.
DR   EMBL; AK303399; BAH13953.1; -; mRNA.
DR   EMBL; AK314238; BAG36907.1; -; mRNA.
DR   EMBL; BC036023; AAH36023.1; -; mRNA.
DR   CCDS; CCDS3735.1; -. [O00444-1]
DR   CCDS; CCDS54803.1; -. [O00444-2]
DR   CCDS; CCDS54804.1; -. [O00444-3]
DR   RefSeq; NP_001177728.1; NM_001190799.1. [O00444-2]
DR   RefSeq; NP_001177730.1; NM_001190801.1. [O00444-3]
DR   RefSeq; NP_055079.3; NM_014264.4. [O00444-1]
DR   UniGene; Hs.172052; -.
DR   PDB; 2N19; NMR; -; A=884-970.
DR   PDB; 3COK; X-ray; 2.25 A; A/B=2-275.
DR   PDB; 4JXF; X-ray; 2.40 A; A=4-269.
DR   PDB; 4N7V; X-ray; 2.76 A; A/B=580-808.
DR   PDB; 4N7Z; X-ray; 2.85 A; A=580-808.
DR   PDB; 4N9J; X-ray; 2.60 A; A/B=581-808.
DR   PDB; 4YUR; X-ray; 2.65 A; A=2-275.
DR   PDB; 4YYP; X-ray; 2.60 A; A=884-970.
DR   PDB; 5LHY; X-ray; 3.31 A; 1/2/3/4/5/6/7/8/9/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U=884-970.
DR   PDB; 5LHZ; X-ray; 2.51 A; A/B/C=884-970.
DR   PDBsum; 2N19; -.
DR   PDBsum; 3COK; -.
DR   PDBsum; 4JXF; -.
DR   PDBsum; 4N7V; -.
DR   PDBsum; 4N7Z; -.
DR   PDBsum; 4N9J; -.
DR   PDBsum; 4YUR; -.
DR   PDBsum; 4YYP; -.
DR   PDBsum; 5LHY; -.
DR   PDBsum; 5LHZ; -.
DR   ProteinModelPortal; O00444; -.
DR   SMR; O00444; -.
DR   BioGrid; 115956; 51.
DR   DIP; DIP-34467N; -.
DR   IntAct; O00444; 29.
DR   MINT; MINT-1460432; -.
DR   STRING; 9606.ENSP00000270861; -.
DR   BindingDB; O00444; -.
DR   ChEMBL; CHEMBL3788; -.
DR   GuidetoPHARMACOLOGY; 2171; -.
DR   iPTMnet; O00444; -.
DR   PhosphoSitePlus; O00444; -.
DR   BioMuta; PLK4; -.
DR   MaxQB; O00444; -.
DR   PaxDb; O00444; -.
DR   PeptideAtlas; O00444; -.
DR   PRIDE; O00444; -.
DR   DNASU; 10733; -.
DR   Ensembl; ENST00000270861; ENSP00000270861; ENSG00000142731. [O00444-1]
DR   Ensembl; ENST00000513090; ENSP00000427554; ENSG00000142731. [O00444-2]
DR   Ensembl; ENST00000514379; ENSP00000423582; ENSG00000142731. [O00444-3]
DR   GeneID; 10733; -.
DR   KEGG; hsa:10733; -.
DR   UCSC; uc003ifo.4; human. [O00444-1]
DR   CTD; 10733; -.
DR   DisGeNET; 10733; -.
DR   GeneCards; PLK4; -.
DR   HGNC; HGNC:11397; PLK4.
DR   HPA; HPA017327; -.
DR   HPA; HPA035026; -.
DR   MalaCards; PLK4; -.
DR   MIM; 605031; gene.
DR   MIM; 616171; phenotype.
DR   neXtProt; NX_O00444; -.
DR   OpenTargets; ENSG00000142731; -.
DR   PharmGKB; PA36205; -.
DR   eggNOG; KOG0575; Eukaryota.
DR   eggNOG; ENOG410XQBP; LUCA.
DR   GeneTree; ENSGT00530000062954; -.
DR   HOVERGEN; HBG053617; -.
DR   InParanoid; O00444; -.
DR   KO; K08863; -.
DR   OMA; FPIIVGR; -.
DR   OrthoDB; EOG091G05NQ; -.
DR   PhylomeDB; O00444; -.
DR   TreeFam; TF101090; -.
DR   BRENDA; 2.7.11.21; 2681.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SignaLink; O00444; -.
DR   SIGNOR; O00444; -.
DR   EvolutionaryTrace; O00444; -.
DR   GeneWiki; PLK4; -.
DR   GenomeRNAi; 10733; -.
DR   PRO; PR:O00444; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000142731; -.
DR   CleanEx; HS_PLK4; -.
DR   ExpressionAtlas; O00444; baseline and differential.
DR   Genevisible; O00444; HS.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0098536; C:deuterosome; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0001741; C:XY body; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007099; P:centriole replication; IMP:UniProtKB.
DR   GO; GO:0097711; P:ciliary basal body docking; TAS:Reactome.
DR   GO; GO:0098535; P:de novo centriole assembly involved in multi-ciliated epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0046601; P:positive regulation of centriole replication; IDA:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0060707; P:trophoblast giant cell differentiation; ISS:UniProtKB.
DR   CDD; cd13114; POLO_box_Plk4_1; 1.
DR   CDD; cd13115; POLO_box_Plk4_2; 1.
DR   CDD; cd13116; POLO_box_Plk4_3; 1.
DR   Gene3D; 3.30.1120.30; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033700; Plk4.
DR   InterPro; IPR000959; POLO_box_dom.
DR   InterPro; IPR033699; POLO_box_Plk4_1.
DR   InterPro; IPR033698; POLO_box_Plk4_2.
DR   InterPro; IPR033696; POLO_box_Plk4_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   PANTHER; PTHR24345:SF64; PTHR24345:SF64; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00659; POLO_box; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50078; POLO_BOX; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Cytoskeleton; Dwarfism; Kinase; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    970       Serine/threonine-protein kinase PLK4.
FT                                /FTId=PRO_0000086567.
FT   DOMAIN       12    265       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      892    956       POLO box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00154}.
FT   NP_BIND      18     26       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    136    136       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING      41     41       ATP. {ECO:0000305}.
FT   MOD_RES     401    401       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     665    665       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     817    817       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ       1     41       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038116.
FT   VAR_SEQ      43     74       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038117.
FT   VARIANT      86     86       Y -> C (in dbSNP:rs34156294).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041027.
FT   VARIANT     146    146       R -> H (in dbSNP:rs35232579).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041028.
FT   VARIANT     226    226       A -> T (in dbSNP:rs35448573).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041029.
FT   VARIANT     232    232       S -> T (in dbSNP:rs3811740).
FT                                {ECO:0000269|PubMed:11489907,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.1}.
FT                                /FTId=VAR_019632.
FT   VARIANT     317    317       P -> L (in dbSNP:rs35049837).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041030.
FT   VARIANT     449    449       N -> D (in dbSNP:rs34906574).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041031.
FT   VARIANT     519    519       W -> S (in dbSNP:rs56043017).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041032.
FT   VARIANT     830    830       E -> D (in dbSNP:rs17012739).
FT                                {ECO:0000269|PubMed:11489907,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.1}.
FT                                /FTId=VAR_041033.
FT   MUTAGEN      41     41       K->M: Abolishes ability to phosphorylate
FT                                CDC25C and CHEK2.
FT                                {ECO:0000269|PubMed:18239451,
FT                                ECO:0000269|PubMed:19164942}.
FT   MUTAGEN     154    154       D->A: Catalytically inactive mutant that
FT                                causes some centrosome amplification
FT                                above background levels when
FT                                overexpressed.
FT                                {ECO:0000269|PubMed:16244668}.
FT   MUTAGEN     170    170       T->D: Activating mutant.
FT                                {ECO:0000269|PubMed:18239451,
FT                                ECO:0000269|PubMed:19164942}.
FT   CONFLICT     34     34       T -> S (in Ref. 2; BAB69958).
FT                                {ECO:0000305}.
FT   CONFLICT     58     58       Q -> K (in Ref. 1; CAA73575).
FT                                {ECO:0000305}.
FT   CONFLICT    333    333       D -> N (in Ref. 3; BAH13823).
FT                                {ECO:0000305}.
FT   CONFLICT    387    387       S -> R (in Ref. 2; BAB69958).
FT                                {ECO:0000305}.
FT   CONFLICT    692    692       F -> S (in Ref. 3; BAH13823).
FT                                {ECO:0000305}.
FT   CONFLICT    696    696       V -> L (in Ref. 2; BAB69958).
FT                                {ECO:0000305}.
FT   CONFLICT    768    768       Y -> F (in Ref. 1; CAA73575).
FT                                {ECO:0000305}.
FT   CONFLICT    842    842       A -> D (in Ref. 2; BAB69958).
FT                                {ECO:0000305}.
FT   HELIX         2      5       {ECO:0000244|PDB:3COK}.
FT   HELIX         9     11       {ECO:0000244|PDB:3COK}.
FT   STRAND       12     20       {ECO:0000244|PDB:3COK}.
FT   STRAND       22     31       {ECO:0000244|PDB:3COK}.
FT   TURN         32     34       {ECO:0000244|PDB:3COK}.
FT   STRAND       37     44       {ECO:0000244|PDB:3COK}.
FT   HELIX        45     50       {ECO:0000244|PDB:3COK}.
FT   HELIX        54     64       {ECO:0000244|PDB:3COK}.
FT   STRAND       75     80       {ECO:0000244|PDB:3COK}.
FT   STRAND       82     90       {ECO:0000244|PDB:3COK}.
FT   HELIX        97    102       {ECO:0000244|PDB:3COK}.
FT   STRAND      104    106       {ECO:0000244|PDB:4JXF}.
FT   HELIX       110    129       {ECO:0000244|PDB:3COK}.
FT   HELIX       139    141       {ECO:0000244|PDB:3COK}.
FT   STRAND      142    144       {ECO:0000244|PDB:3COK}.
FT   STRAND      150    152       {ECO:0000244|PDB:3COK}.
FT   TURN        158    161       {ECO:0000244|PDB:4JXF}.
FT   HELIX       193    206       {ECO:0000244|PDB:3COK}.
FT   HELIX       217    225       {ECO:0000244|PDB:4JXF}.
FT   HELIX       236    245       {ECO:0000244|PDB:3COK}.
FT   HELIX       250    252       {ECO:0000244|PDB:3COK}.
FT   HELIX       256    259       {ECO:0000244|PDB:3COK}.
FT   TURN        263    265       {ECO:0000244|PDB:3COK}.
FT   HELIX       587    590       {ECO:0000244|PDB:4N9J}.
FT   STRAND      602    605       {ECO:0000244|PDB:4N9J}.
FT   STRAND      607    613       {ECO:0000244|PDB:4N9J}.
FT   STRAND      619    627       {ECO:0000244|PDB:4N9J}.
FT   STRAND      630    639       {ECO:0000244|PDB:4N9J}.
FT   STRAND      645    649       {ECO:0000244|PDB:4N9J}.
FT   HELIX       651    654       {ECO:0000244|PDB:4N9J}.
FT   STRAND      671    674       {ECO:0000244|PDB:4N9J}.
FT   HELIX       675    677       {ECO:0000244|PDB:4N9J}.
FT   HELIX       680    682       {ECO:0000244|PDB:4N9J}.
FT   HELIX       683    698       {ECO:0000244|PDB:4N9J}.
FT   STRAND      700    706       {ECO:0000244|PDB:4N9J}.
FT   STRAND      708    716       {ECO:0000244|PDB:4N9J}.
FT   STRAND      723    727       {ECO:0000244|PDB:4N9J}.
FT   STRAND      732    735       {ECO:0000244|PDB:4N9J}.
FT   STRAND      740    743       {ECO:0000244|PDB:4N9J}.
FT   STRAND      749    752       {ECO:0000244|PDB:4N9J}.
FT   HELIX       755    759       {ECO:0000244|PDB:4N9J}.
FT   HELIX       765    793       {ECO:0000244|PDB:4N9J}.
FT   STRAND      800    804       {ECO:0000244|PDB:4N9J}.
FT   STRAND      887    893       {ECO:0000244|PDB:5LHZ}.
FT   TURN        894    896       {ECO:0000244|PDB:5LHZ}.
FT   STRAND      897    902       {ECO:0000244|PDB:5LHZ}.
FT   STRAND      905    911       {ECO:0000244|PDB:5LHZ}.
FT   STRAND      916    922       {ECO:0000244|PDB:5LHZ}.
FT   STRAND      924    929       {ECO:0000244|PDB:5LHZ}.
FT   TURN        931    933       {ECO:0000244|PDB:2N19}.
FT   STRAND      935    939       {ECO:0000244|PDB:5LHZ}.
FT   HELIX       946    961       {ECO:0000244|PDB:5LHZ}.
SQ   SEQUENCE   970 AA;  108972 MW;  4D56F5FD983211A6 CRC64;
     MATCIGEKIE DFKVGNLLGK GSFAGVYRAE SIHTGLEVAI KMIDKKAMYK AGMVQRVQNE
     VKIHCQLKHP SILELYNYFE DSNYVYLVLE MCHNGEMNRY LKNRVKPFSE NEARHFMHQI
     ITGMLYLHSH GILHRDLTLS NLLLTRNMNI KIADFGLATQ LKMPHEKHYT LCGTPNYISP
     EIATRSAHGL ESDVWSLGCM FYTLLIGRPP FDTDTVKNTL NKVVLADYEM PSFLSIEAKD
     LIHQLLRRNP ADRLSLSSVL DHPFMSRNSS TKSKDLGTVE DSIDSGHATI STAITASSST
     SISGSLFDKR RLLIGQPLPN KMTVFPKNKS STDFSSSGDG NSFYTQWGNQ ETSNSGRGRV
     IQDAEERPHS RYLRRAYSSD RSGTSNSQSQ AKTYTMERCH SAEMLSVSKR SGGGENEERY
     SPTDNNANIF NFFKEKTSSS SGSFERPDNN QALSNHLCPG KTPFPFADPT PQTETVQQWF
     GNLQINAHLR KTTEYDSISP NRDFQGHPDL QKDTSKNAWT DTKVKKNSDA SDNAHSVKQQ
     NTMKYMTALH SKPEIIQQEC VFGSDPLSEQ SKTRGMEPPW GYQNRTLRSI TSPLVAHRLK
     PIRQKTKKAV VSILDSEEVC VELVKEYASQ EYVKEVLQIS SDGNTITIYY PNGGRGFPLA
     DRPPSPTDNI SRYSFDNLPE KYWRKYQYAS RFVQLVRSKS PKITYFTRYA KCILMENSPG
     ADFEVWFYDG VKIHKTEDFI QVIEKTGKSY TLKSESEVNS LKEEIKMYMD HANEGHRICL
     ALESIISEEE RKTRSAPFFP IIIGRKPGST SSPKALSPPP SVDSNYPTRE RASFNRMVMH
     SAASPTQAPI LNPSMVTNEG LGLTTTASGT DISSNSLKDC LPKSAQLLKS VFVKNVGWAT
     QLTSGAVWVQ FNDGSQLVVQ AGVSSISYTS PNGQTTRYGE NEKLPDYIKQ KLQCLSSILL
     MFSNPTPNFH
//
